A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Latest Information Update: 22 Aug 2024
At a glance
- Drugs CLBR 001-SWI 019-Abbvie/California Institute for Biomedical Research (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors Calibra Medical
Most Recent Events
- 20 Aug 2024 Status changed from active, no longer recruiting to completed.
- 23 Jan 2024 Planned primary completion date changed from 1 Aug 2023 to 1 Apr 2024.
- 27 Jun 2023 Planned End Date changed from 1 Apr 2024 to 1 Jun 2024.